Výsledky vyhledávání - "Sheldrake HM"

Akademický článek

Sidechain structure-activity relationships of cyclobutane-based small molecule αvβ3 antagonists.

Autor: Throup A; Institute of Cancer Therapeutics, University of Bradford Bradford BD7 1DP UK h.sheldrake@bradford.ac.uk., Zraikat MS; Institute of Cancer Therapeutics, University of Bradford Bradford BD7 1DP UK h.sheldrake@bradford.ac.uk., Gordon A; Institute of Cancer Therapeutics, University of Bradford Bradford BD7 1DP UK h.sheldrake@bradford.ac.uk., Jafarinejad Soumehsaraei S; Institute of Cancer Therapeutics, University of Bradford Bradford BD7 1DP UK h.sheldrake@bradford.ac.uk., Haase KD; Institute of Cancer Therapeutics, University of Bradford Bradford BD7 1DP UK h.sheldrake@bradford.ac.uk., Patterson LH; Institute of Cancer Therapeutics, University of Bradford Bradford BD7 1DP UK h.sheldrake@bradford.ac.uk., Cooper PA; Institute of Cancer Therapeutics, University of Bradford Bradford BD7 1DP UK h.sheldrake@bradford.ac.uk., Hanlon K; Institute of Cancer Therapeutics, University of Bradford Bradford BD7 1DP UK h.sheldrake@bradford.ac.uk., Loadman PM; Institute of Cancer Therapeutics, University of Bradford Bradford BD7 1DP UK h.sheldrake@bradford.ac.uk., Sutherland M; Institute of Cancer Therapeutics, University of Bradford Bradford BD7 1DP UK h.sheldrake@bradford.ac.uk., Shnyder SD; Institute of Cancer Therapeutics, University of Bradford Bradford BD7 1DP UK h.sheldrake@bradford.ac.uk., Sheldrake HM; Institute of Cancer Therapeutics, University of Bradford Bradford BD7 1DP UK h.sheldrake@bradford.ac.uk.

Publikováno v: RSC medicinal chemistry [RSC Med Chem] 2024 Sep 13. Date of Electronic Publication: 2024 Sep 13.

Zobrazit plný text záznamu

Akademický článek

Overcoming Vemurafenib Resistance in Metastatic Melanoma: Targeting Integrins to Improve Treatment Efficacy.

Autor: Boz Er AB; Institute of Cancer Therapeutics, School of Pharmacy and Medical Sciences, University of Bradford, Bradford BD7 1DP, UK., Sheldrake HM; Institute of Cancer Therapeutics, School of Pharmacy and Medical Sciences, University of Bradford, Bradford BD7 1DP, UK., Sutherland M; School of Chemistry and Biosciences, University of Bradford, Bradford BD7 1DP, UK.

Publikováno v: International journal of molecular sciences [Int J Mol Sci] 2024 Jul 20; Vol. 25 (14). Date of Electronic Publication: 2024 Jul 20.

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Synthesis and Biological Evaluation of Cyclobutane-Based β3 Integrin Antagonists: A Novel Approach to Targeting Integrins for Cancer Therapy.

Autor: Sutherland M; Institute of Cancer Therapeutics, University of Bradford, Bradford BD7 1DP, UK., Gordon A; Institute of Cancer Therapeutics, University of Bradford, Bradford BD7 1DP, UK., Al-Shammari FOFO; Institute of Cancer Therapeutics, University of Bradford, Bradford BD7 1DP, UK., Throup A; Institute of Cancer Therapeutics, University of Bradford, Bradford BD7 1DP, UK., Cilia La Corte A; Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds LS2 9JT, UK., Philippou H; Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds LS2 9JT, UK., Shnyder SD; Institute of Cancer Therapeutics, University of Bradford, Bradford BD7 1DP, UK., Patterson LH; Institute of Cancer Therapeutics, University of Bradford, Bradford BD7 1DP, UK., Sheldrake HM; Institute of Cancer Therapeutics, University of Bradford, Bradford BD7 1DP, UK.

Publikováno v: Cancers [Cancers (Basel)] 2023 Aug 08; Vol. 15 (16). Date of Electronic Publication: 2023 Aug 08.

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Probing cytochrome P450 (CYP) bioactivation with chloromethylindoline bioprecursors derived from the duocarmycin family of compounds.

Autor: Ortuzar N; Department of Pharmaceutical and Biological Chemistry, UCL School of Pharmacy, 29-39 Brunswick Square, London WC1N 1AX, UK., Karu K; Department of Pharmaceutical and Biological Chemistry, UCL School of Pharmacy, 29-39 Brunswick Square, London WC1N 1AX, UK., Presa D; Institute of Cancer Therapeutics, School of Pharmacy and Medical Sciences, Faculty of Life Sciences, University of Bradford, BD7 1DP, UK., Morais GR; Institute of Cancer Therapeutics, School of Pharmacy and Medical Sciences, Faculty of Life Sciences, University of Bradford, BD7 1DP, UK., Sheldrake HM; Institute of Cancer Therapeutics, School of Pharmacy and Medical Sciences, Faculty of Life Sciences, University of Bradford, BD7 1DP, UK., Shnyder SD; Institute of Cancer Therapeutics, School of Pharmacy and Medical Sciences, Faculty of Life Sciences, University of Bradford, BD7 1DP, UK., Barnieh FM; Institute of Cancer Therapeutics, School of Pharmacy and Medical Sciences, Faculty of Life Sciences, University of Bradford, BD7 1DP, UK., Loadman PM; Institute of Cancer Therapeutics, School of Pharmacy and Medical Sciences, Faculty of Life Sciences, University of Bradford, BD7 1DP, UK., Patterson LH; Institute of Cancer Therapeutics, School of Pharmacy and Medical Sciences, Faculty of Life Sciences, University of Bradford, BD7 1DP, UK., Pors K; Institute of Cancer Therapeutics, School of Pharmacy and Medical Sciences, Faculty of Life Sciences, University of Bradford, BD7 1DP, UK. Electronic address: k.pors1@bradford.ac.uk., Searcey M; School of Pharmacy, University of East Anglia, Norwich Research Park, Norwich NR4 7TJ, UK. Electronic address: M.Searcey@uea.ac.uk.

Publikováno v: Bioorganic & medicinal chemistry [Bioorg Med Chem] 2021 Jun 15; Vol. 40, pp. 116167. Date of Electronic Publication: 2021 Apr 21.

Zobrazit plný text záznamu

Akademický článek

Exploration of [2 + 2 + 2] cyclotrimerisation methodology to prepare tetrahydroisoquinoline-based compounds with potential aldo-keto reductase 1C3 target affinity.

Autor: Santos ARN; Institute of Cancer Therapeutics , Faculty of Life Sciences , University of Bradford , West Yorkshire , BD7 1DP , UK . Email: k.pors1@bradford.ac.uk., Sheldrake HM; Institute of Cancer Therapeutics , Faculty of Life Sciences , University of Bradford , West Yorkshire , BD7 1DP , UK . Email: k.pors1@bradford.ac.uk., Ibrahim AIM; Institute of Cancer Therapeutics , Faculty of Life Sciences , University of Bradford , West Yorkshire , BD7 1DP , UK . Email: k.pors1@bradford.ac.uk., Danta CC; Institute of Cancer Therapeutics , Faculty of Life Sciences , University of Bradford , West Yorkshire , BD7 1DP , UK . Email: k.pors1@bradford.ac.uk., Bonanni D; Department of Science and Drug Technology , University of Torino , Via Pietro Giuria 9 , 10125 Torino , Italy., Daga M; Department of Science and Drug Technology , University of Torino , Via Pietro Giuria 9 , 10125 Torino , Italy., Oliaro-Bosso S; Department of Science and Drug Technology , University of Torino , Via Pietro Giuria 9 , 10125 Torino , Italy., Boschi D; Department of Science and Drug Technology , University of Torino , Via Pietro Giuria 9 , 10125 Torino , Italy., Lolli ML; Department of Science and Drug Technology , University of Torino , Via Pietro Giuria 9 , 10125 Torino , Italy., Pors K; Institute of Cancer Therapeutics , Faculty of Life Sciences , University of Bradford , West Yorkshire , BD7 1DP , UK . Email: k.pors1@bradford.ac.uk.

Publikováno v: MedChemComm [Medchemcomm] 2019 Jun 27; Vol. 10 (8), pp. 1476-1480. Date of Electronic Publication: 2019 Jun 27 (Print Publication: 2019).

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání